View of Cost-Utility Analysis of First-Line Regimen between Cisplatin Plus Pemetrexed and Carboplatin plus Paclitaxel in Advanced Non-Squamous Non-Small-Cell Lung Cancer

Return to Article Details Cost-Utility Analysis of First-Line Regimen between Cisplatin Plus Pemetrexed and Carboplatin plus Paclitaxel in Advanced Non-Squamous Non-Small-Cell Lung Cancer Download Download PDF